IP Library › Granted Patent US 8,999,292
Granted Patent B2
US 8,999,292 · App. 13/838,473 · Granted Apr 7, 2015

Methods for treating and diagnosing blinding eye diseases

Inventor: Shelley Romayne Boyd (Toronto, CA)
Assignee: Translatum Medicus Inc.
A61K49/0008A61K31/415
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,292
App. No.
13/838,473
Granted
Apr 7, 2015
Kind
B2
Abstract

This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).

Claims (18)

1. A method for reducing the rate of progression of dry age related macular degeneration (AMD), comprising intravitreally administering to a subject in need thereof an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

each of R 1 and R 2 is independently H or a C 1 -C 6 alkyl and

R 3 is H or a C 1 -C 6 alkyl.

2. The method of claim 1 , wherein the compound of Formula I is bindarit.

3. The method of claim 1 , wherein the dry AMD is early stage AMD or atrophic AMD.

4. The method of claim 1 , wherein the method reduces the rate of progression to late disease.

5. The method of claim 1 , wherein the method reduces the rate of expansion of geographic atrophy.

6. A method for reducing the rate of expansion of geographic atrophy in an eye of a subject afflicted with dry age related macular degeneration (AMD), comprising ophthalmically administering to the subject an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

each of R 1 and R 2 is independently H or a C 1 -C 6 alkyl, and

R 3 is H or a C 1 -C 6 alkyl.

7. The method of claim 6 , wherein the compound of Formula I is bindarit.

8. The method of claim 7 , wherein the bindarit is formulated for ophthalmic administration.

9. The method of claim 8 , wherein the ophthalmic administration is intravitreal or intraocular administration.

10. The method of 9 , wherein the bindarit is formulated for sustained release.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2014
From: BOYD, SHELLEY ROMAYNE
To: TRANSLATUM MEDICUS INC.
Reel/Frame 032495/0756 →
Continuity (4)
Provisional Application 61640854 · May 1, 2012
Provisional Application 61641393 · May 2, 2012
Provisional Application 61693226 · Aug 24, 2012
Related Publication 20130295014A1 · Nov 7, 2013